MedTrace Logo

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

NCT00346983 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2008-05-12

No results posted yet for this study

Summary

This research is being conducted to look at the effects of an intraocular drug (pegaptanib, also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that often occurs following cataract surgery in patients with diabetic eye disease. Swelling in the retina can lead to blurry vision, and Macugen may reduce this swelling. Eyedrops that decrease inflammation also may help to stop some of the swelling. We are testing this drug (pegaptanib) to see if it can decrease swelling in the retina and improve vision in patients with diabetes who are having cataract surgery.

Conditions

  • Cystoid Macular Edema

Interventions

DRUG

Pegaptanib sodium

0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections

DRUG

Control

Sham injection, every 6 weeks, up to a total of 3 sham injections

Sponsors & Collaborators

Principal Investigators

  • Oliver D. Schein, MD, MPH, MBA · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-04-30
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346983 on ClinicalTrials.gov